
  
    
      
        
        Autoimmune_NNP diseases_NNS afflict_VB a_DT large_JJ segment_NN of_IN the_DT population_NN in_IN Western_JJ countries_NNS ._. Many_JJ
        of_IN them_PRP have_VBP been_VBN described_VBN ,_, and_CC rheumatoid_NN arthritis_NN ,_, type_NN I_PRP diabetes_NN (_( also_RB called_VBN
        insulin-dependent_JJ diabetes_NN mellitus_JJ )_) ,_, multiple_JJ sclerosis_NN ,_, and_CC systemic_JJ lupus_JJ erythematosus_JJ
        (_( SLE_NNP )_) are_VBP among_IN the_DT most_RBS common_JJ ._. Although_IN tremendous_JJ progress_NN has_VBZ been_VBN made_VBN in_IN disease_NN
        management_NN over_IN the_DT last_JJ decade_NN ,_, cures_NNS for_IN these_DT diseases_NNS have_VBP not_RB yet_RB been_VBN found_VBN ._.
        Consequently_RB ,_, a_DT large_JJ research_NN effort_NN is_VBZ sustained_VBN in_IN this_DT field_NN ._. In_IN addition_NN ,_, autoimmunity_NN
        has_VBZ intrigued_VBN basic_JJ immunologists_NNS since_IN the_DT early_JJ realization_NN that_IN the_DT ability_NN to_TO
        discriminate_JJ self_NN from_IN non-self_JJ was_VBD at_IN the_DT core_NN of_IN the_DT immune_JJ system_NN 's_POS ability_NN to_TO protect_VB
        an_DT organism_NN from_IN pathogens_NNS while_IN avoiding_VBG self-destruction_JJ ._. A_DT failure_NN of_IN this_DT mechanism_NN
        results_NNS in_IN autoimmune_JJ reactions_NNS that_WDT often_RB lead_VB to_TO clinical_JJ disease_NN ._. In_IN spite_NN of_IN massive_JJ
        research_NN efforts_NNS ,_, the_DT mechanisms_NNS by_IN which_WDT autoimmune_JJ diseases_NNS develop_VBP are_VBP not_RB clearly_RB
        understood_VBN ._. Genetic_JJ predisposition_NN as_RB well_RB as_IN environmental_JJ triggers_VBZ plays_VBZ a_DT role_NN ,_, but_CC the_DT
        identity_NN of_IN these_DT factors_NNS has_VBZ been_VBN largely_RB elusive_JJ ._. The_DT identification_NN of_IN the_DT most_RBS common_JJ
        genetic_JJ and_CC environmental_JJ factors_NNS that_WDT set_VBD off_IN autoimmunity_NN may_MD lead_VB to_TO a_DT better_JJR
        understanding_NN of_IN the_DT ensuing_VBG pathogenesis_NNS ,_, and_CC offers_VBZ the_DT best_JJS hope_VBP for_IN improved_VBN therapies_NNS ,_,
        and_CC ultimately_RB ,_, cures_NNS ._.
        So_RB far_RB ,_, animal_NN models_NNS have_VBP proved_VBN the_DT best_JJS way_NN to_TO probe_VB the_DT mechanisms_NNS of_IN disease_NN in_IN
        general_JJ ,_, and_CC autoimmune_JJ diseases_NNS in_IN particular_NN ._. In_IN the_DT past_JJ few_JJ decades_NNS ,_, the_DT mouse_NN has_VBZ
        become_VBN the_DT model_NN of_IN choice_NN for_IN experimental_JJ medicine_NN ,_, and_CC the_DT rat_NN is_VBZ following_VBG close_NN
        behind_IN ._. Starting_VBG in_IN the_DT early_JJ twentieth_NN century_NN at_IN the_DT Jackson_NNP Laboratory_NNP (_( Bar_NNP Harbor_NNP ,_,
        Maine_NNP ,_, United_NNP States_NNPS )_) ,_, the_DT production_NN of_IN inbred_JJ strains_NNS of_IN mice_NNS and_CC the_DT systematic_JJ
        collection_NN and_CC characterization_NN of_IN naturally_RB occurring_VBG mutants_NNS have_VBP created_VBN the_DT building_NN
        blocks_NNS on_IN which_WDT much_JJ of_IN the_DT research_NN using_VBG animal_NN models_NNS is_VBZ now_RB based_VBN ._. Inbred_NNP strains_NNS are_VBP
        collections_NNS of_IN genetically_RB identical_JJ animals_NNS obtained_VBN through_IN selective_JJ breeding_NN ._. These_DT
        strains_NNS have_VBP provided_VBN homogenous_JJ experimental_JJ groups_NNS ,_, with_IN interindividual_NN variability_NN
        reduced_VBN to_TO environmental_JJ (_( and_CC stochastic_JJ )_) factors_NNS ._. In_IN addition_NN ,_, inbred_JJ strains_NNS have_VBP an_DT
        assortment_NN of_IN distinct_JJ phenotypes_NNS that_WDT have_VBP then_RB been_VBN exploited_VBN as_IN models_NNS of_IN human_JJ
        diseases_NNS ._.
        Since_IN the_DT 1980_CD s_VBZ ,_, techniques_NNS have_VBP been_VBN developed_VBN to_TO manipulate_VB the_DT mouse_NN genome_NN ._. Specific_JJ
        genes_NNS now_RB can_MD be_VB routinely_RB over-expressed_JJ as_IN transgenes_NNS ,_, or_CC eliminated_VBN by_IN gene_NN targeting_VBG ,_,
        which_WDT creates_VBZ a_DT “ knockout_NN” (_( Smithies_NNP 1993_CD ;_: Wassarman_NNP and_CC DePamphilis_NNP 1993_CD )_) ._. This_DT approach_NN ,_,
        known_VBN as_IN reverse_NN genetics_NNS ,_, has_VBZ shown_VBN itself_PRP to_TO be_VB a_DT powerful_JJ tool_NN with_IN which_WDT to_TO evaluate_VB
        the_DT role_NN of_IN individual_JJ genes_NNS in_IN various_JJ biological_JJ processes_NNS ._. The_DT use_NN of_IN genetically_RB
        engineered_VBN mouse_NN models_NNS will_MD likely_RB play_VB a_DT major_JJ role_NN in_IN deciphering_VBG the_DT function_NN of_IN a_DT
        multitude_NN of_IN new_JJ genes_NNS revealed_VBD in_IN the_DT recently_RB completed_VBN sequence_NN of_IN the_DT mouse_NN genome_NN
        (_( Mouse_NNP Genome_NNP Sequencing_NNP Consortium_NNP 2002_CD )_) ._.
        Interestingly_RB ,_, the_DT percentage_NN of_IN mouse_NN genes_NNS without_IN any_DT homolog_NN currently_RB detectable_JJ in_IN
        the_DT human_JJ genome_NN (_( and_CC vice_NN versa_RB )_) has_VBZ been_VBN estimated_VBN to_TO be_VB less_JJR than_IN 1_CD %_NN ,_, a_DT fact_NN that_WDT
        strengthens_VBZ the_DT validity_NN of_IN mouse_NN models_NNS of_IN human_JJ diseases_NNS ._. However_RB ,_, one_CD has_VBZ to_TO be_VB careful_JJ
        in_IN directly_RB applying_VBG data_NNS obtained_VBN from_IN animal_NN models_NNS to_TO human_JJ diseases_NNS ._. Most_JJS human_JJ
        autoimmune_JJ diseases_NNS show_VBP an_DT extremely_RB heterogeneous_JJ clinical_JJ presentation_NN ,_, which_WDT animal_NN
        models_NNS present_JJ as_IN simplified_VBN versions_NNS ._. A_DT mouse_NN model_NN ,_, as_IN in_IN any_DT reductionist_NN approach_NN ,_, is_VBZ
        both_DT inconvenient_JJ ,_, because_IN it_PRP provides_VBZ only_RB a_DT partial_JJ representation_NN of_IN the_DT real_JJ biological_JJ
        complexity_NN underlying_VBG the_DT human_JJ disease_NN ,_, and_CC advantageous_JJ ,_, because_IN it_PRP is_VBZ a_DT more_RBR tractable_JJ
        tool_NN with_IN which_WDT to_TO probe_VB mechanistic_JJ issues_NNS ._. In_IN addition_NN ,_, a_DT number_NN of_IN differences_NNS exist_VBP
        between_IN the_DT human_NN and_CC rodent_NN immune_JJ systems_NNS (_( Mestas_NNP and_CC Hughes_NNP 2004_CD )_) ._. Since_IN immune_JJ
        dysfunctions_NNS are_VBP at_IN the_DT root_NN of_IN autoimmune_JJ diseases_NNS ,_, such_JJ differences_NNS may_MD limit_VB
        extrapolations_NNS from_IN animal_NN models_NNS to_TO autoimmune_JJ patients_NNS ._.
        Nonetheless_RB ,_, animal_NN models_NNS are_VBP at_IN the_DT core_NN of_IN autoimmune_JJ research_NN ,_, and_CC a_DT large_JJ body_NN of_IN
        literature_NN reflects_VBZ the_DT many_JJ advances_NNS brought_VBN by_IN these_DT models_NNS in_IN terms_NNS of_IN deciphering_VBG
        disease_NN mechanisms_NNS ._. The_DT relative_JJ lack_NN of_IN progress_NN in_IN certain_JJ human_JJ autoimmune_JJ diseases_NNS for_IN
        which_WDT an_DT animal_NN model_NN does_VBZ not_RB exist_VB ,_, such_JJ as_IN neuropsychiatric_JJ lupus_JJ ,_, corroborates_NNS the_DT
        indispensable_JJ role_NN played_VBN by_IN animal_NN models_NNS ._. Three_CD basic_JJ types_NNS of_IN animal_NN models_NNS have_VBP been_VBN
        used_VBN in_IN autoimmune_JJ research_NN :_: spontaneous_JJ models_NNS ,_, induced_VBN models_NNS ,_, and_CC genetically_RB engineered_VBN
        models_NNS ._. The_DT latter_JJ category_NN has_VBZ been_VBN further_JJ subdivided_JJ into_IN transgenic_JJ and_CC knockout_NN
        strains_NNS (_( Table_NNP 1_LS )_) ._.
        Spontaneous_NNP models_NNS were_VBD produced_VBN through_IN fortuitous_JJ observations_NNS of_IN clinical_JJ symptoms_NNS
        reminiscent_NN of_IN a_DT given_VBN human_JJ autoimmune_JJ disease_NN developing_VBG in_IN a_DT given_VBN mouse_NN strain_NN ,_, or_CC in_IN
        crosses_VBZ between_IN mouse_NN strains_NNS ._. This_DT happened_VBD ,_, for_IN example_NN ,_, with_IN the_DT nonobese_NN diabetic_JJ (_( NOD_NNP )_)
        mouse_NN ,_, which_WDT developed_VBD type_NN 1_CD diabetes_NN ,_, and_CC the_DT hybrid_NN between_IN the_DT New_NNP Zealand_NNP Black_NNP (_( NZB_NNP )_)
        and_CC the_DT New_NNP Zealand_NNP White_NNP (_( NZW_NNP )_) mouse_NN ,_, (_( NZB_NNP ×_NN NZW_NNP )_) F_NN 1_CD ,_, which_WDT developed_VBD a_DT lupus-like_JJ
        disease_NN ._.
        Unfortunately_RB ,_, spontaneous_JJ models_NNS are_VBP not_RB available_JJ for_IN all_DT human_JJ autoimmune_JJ diseases_NNS ._.
        Therefore_RB ,_, scientists_NNS have_VBP created_VBN induced_VBN models_NNS ,_, often_RB by_IN exposing_VBG the_DT animals_NNS to_TO high_JJ
        doses_NNS of_IN a_DT suspected_VBN autoantigen_NN at_IN the_DT same_JJ time_NN as_IN stimulating_VBG the_DT immune_JJ system_NN ._.
        Interestingly_RB ,_, marked_VBD differences_NNS exist_VBP between_IN strains_NNS in_IN their_PRP$ responses_NNS to_TO these_DT
        autoimmune_JJ inductions_NNS that_WDT reflect_VBP genetic_JJ variation_NN associated_VBN with_IN susceptibility_NN to_TO
        autoimmune_JJ diseases_NNS ._. For_IN this_DT reason_NN ,_, induced_VBN models_NNS have_VBP been_VBN limited_VBN to_TO a_DT small_JJ number_NN of_IN
        strains_NNS ._. For_IN example_NN ,_, experimental_JJ autoimmune_JJ encephalomyelitis_NNS has_VBZ been_VBN widely_RB used_VBN as_IN a_DT
        model_NN of_IN multiple_JJ sclerosis_NN ._. In_IN this_DT model_NN ,_, spinal_JJ cord_NN homogenate_NN or_CC a_DT protein_NN derivative_JJ
        such_JJ as_IN myelin_NN basic_JJ protein_NN is_VBZ injected_VBN with_IN a_DT mixture_NN of_IN potent_JJ immunostimulants_NNS ,_, most_RBS
        commonly_RB in_IN mice_NNS from_IN the_DT SJL_NNP strain_NN ._. Another_DT example_NN of_IN an_DT induced_VBN model_NN is_VBZ
        collagen-induced_JJ arthritis_NN ,_, which_WDT has_VBZ been_VBN used_VBN to_TO study_VB rheumatoid_NN arthritis_NN ._. In_IN this_DT
        model_NN ,_, type_NN II_NNP collagen_NN ,_, a_DT joint_JJ component_NN ,_, is_VBZ injected_VBN also_RB with_IN immunostimulants_NNS ,_, most_RBS
        commonly_RB into_IN mice_NNS from_IN the_DT DBA_NNP /_NN 1_CD strain_NN ._.
        Finally_RB ,_, the_DT ability_NN to_TO turn_VB specific_JJ genes_NNS on_IN or_CC off_RP ,_, in_IN specific_JJ cell_NN types_NNS and_CC /_NN or_CC at_IN
        specific_JJ times_NNS ,_, has_VBZ created_VBN a_DT plethora_NN of_IN mouse_NN models_NNS limited_JJ only_RB by_IN the_DT immunologist_NN 's_POS
        imagination_NN ._. Genes_NNP suspected_VBD to_TO play_VB a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN various_JJ autoimmune_JJ
        diseases_NNS have_VBP been_VBN evaluated_VBN this_DT way_NN ,_, and_CC those_DT studies_NNS have_VBP been_VBN very_RB informative_JJ in_IN
        mapping_NN out_IN functional_JJ pathways_NNS that_WDT are_VBP targeted_VBN in_IN these_DT diseases_NNS ._. However_RB ,_, these_DT models_NNS
        have_VBP intrinsic_JJ problems_NNS that_WDT have_VBP become_VBN more_RBR apparent_JJ in_IN the_DT past_JJ few_JJ years_NNS ,_, and_CC require_VB
        careful_JJ controls_NNS to_TO avoid_VB possible_JJ misinterpretation_NN ._. These_DT problems_NNS are_VBP a_DT result_NN of_IN the_DT
        fundamental_JJ way_NN in_IN which_WDT transgenic_JJ and_CC knockout_NN strains_NNS are_VBP produced_VBN ._. When_WRB a_DT piece_NN of_IN DNA_NNP
        carrying_VBG the_DT gene_NN of_IN interest_NN is_VBZ injected_VBN as_IN a_DT “ transgene_NN” into_IN fertilized_VBN eggs_NNS ,_, it_PRP
        integrates_NNS randomly_RB into_IN the_DT genome_NN ,_, and_CC in_IN doing_VBG so_RB ,_, potentially_RB modifies_VBZ the_DT expression_NN
        of_IN the_DT gene_NN it_PRP integrates_NNS into_IN ._. Since_IN all_DT genetic_JJ studies_NNS have_VBP recognized_VBN that_IN a_DT large_JJ
        number_NN of_IN genes_NNS are_VBP involved_VBN in_IN autoimmune_JJ disease_NN susceptibility_NN ,_, the_DT potential_NN for_IN a_DT
        transgene_NN to_TO hit_VB one_CD of_IN those_DT susceptibility_NN genes_NNS is_VBZ not_RB negligible_JJ ._. This_DT potentially_RB
        confounding_VBG factor_NN is_VBZ usually_RB controlled_VBN by_IN producing_VBG and_CC comparing_VBG several_JJ independent_JJ
        transgenic_JJ lines_NNS ._.
        More_RBR problematic_JJ is_VBZ the_DT interpretation_NN of_IN results_NNS obtained_VBN with_IN knockout_NN models_NNS ._. A_DT gene_NN
        is_VBZ “ knocked_VBN out_IN” (_( KO_NNP )_) by_IN homologous_RB recombination_NN of_IN a_DT disrupting_VBG piece_NN of_IN DNA_NNP within_IN that_DT
        gene_NN ._. This_DT genetic_JJ manipulation_NN takes_VBZ place_NN in_IN embryonic_JJ stem_NN (_( ES_NNP )_) cells_NNS ,_, which_WDT once_RB
        mutated_VBN ,_, are_VBP introduced_VBN into_IN the_DT inner_JJ cavity_NN of_IN a_DT blastocyst_NN (_( very_RB early_JJ mouse_NN embryo_NN )_) ,_,
        creating_VBG chimeric_JJ embryos_NNS that_WDT are_VBP put_VBN back_RB into_IN female_JJ mice_NNS that_WDT carry_VBP the_DT pregnancy_NN to_TO
        term_VB ._. After_IN multiple_JJ trials_NNS (_( and_CC errors_NNS )_) ,_, ES_NNP cell_NN lines_NNS from_IN the_DT 129_CD strain_NN and_CC blastocysts_NNS
        from_IN the_DT C_NNP 57_CD BL_NNP /_NN 6_CD (_( B_NNP 6_CD )_) strain_NN have_VBP shown_VBN themselves_PRP to_TO be_VB superior_JJ in_IN terms_NNS of_IN efficiency_NN
        and_CC reliability_NN ._. Consequently_RB ,_, this_DT strain_NN combination_NN is_VBZ at_IN the_DT origin_NN of_IN the_DT overwhelming_JJ
        majority_NN of_IN knockout_NN strains_NNS ._. Although_IN the_DT chimeric_JJ mice_NNS are_VBP usually_RB backcrossed_JJ to_TO B_NNP 6_CD to_TO
        dilute_VB the_DT contribution_NN of_IN the_DT 129_CD genome_NN ,_, the_DT knockout_NN strains_NNS are_VBP always_RB a_DT mixture_NN of_IN the_DT
        two_CD genomes_NNS (_( Figure_NN 1_LS )_) ._. Most_JJS importantly_RB ,_, a_DT large_JJ region_NN flanking_VBG the_DT KO_NNP gene_NN remains_NNS of_IN
        129_CD origin_NN ,_, unless_IN extreme_JJ measures_NNS are_VBP taken_VBN to_TO select_VB for_IN recombination_NN between_IN tightly_RB
        linked_VBN markers_NNS ._. There_EX have_VBP been_VBN sporadic_JJ reports_NNS of_IN phenotypes_NNS initially_RB attributed_VBD to_TO
        deficiency_NN in_IN the_DT expression_NN of_IN a_DT given_VBN gene_NN that_WDT disappeared_VBD with_IN additional_JJ backcrosses_NNS
        to_TO B_NNP 6_CD ._. The_DT only_RB possible_JJ interpretation_NN was_VBD that_IN these_DT phenotypes_NNS were_VBD in_IN fact_NN due_JJ to_TO 129_CD
        alleles_NNS that_WDT were_VBD replaced_VBN by_IN B_NNP 6_CD alleles_NNS with_IN further_JJ backcrossing_VBG ._.
        The_DT production_NN of_IN autoantibodies_NNS and_CC mild_JJ antibody-related_JJ renal_JJ pathology_NN ,_, highly_RB
        relevant_JJ to_TO autoimmune_JJ diseases_NNS ,_, especially_RB SLE_NNP ,_, has_VBZ been_VBN reported_VBN independently_RB in_IN four_CD
        mouse_NN models_NNS using_VBG the_DT (_( 129_CD ×_NN B_NNP 6_CD )_) genetic_JJ background_NN (_( Obara_NNP et_CC al_NN ._. 1979_CD ;_: Botto_NNP et_CC al_NN 1998_CD ;_:
        Bickerstaff_NNP et_CC al_NN ._. 1999_CD ;_: Santiago-_NNP Raber_NNP et_CC al_NN ._. 2001_CD )_) ._. It_PRP is_VBZ generally_RB accepted_VBN that_IN genetic_JJ
        susceptibility_NN to_TO autoimmune_JJ diseases_NNS is_VBZ conferred_VBD by_IN multiple_JJ highly_RB interactive_JJ genes_NNS
        that_WDT have_VBP small_JJ individual_JJ effects_NNS ._. In_IN this_DT context_NN ,_, the_DT autoimmune_JJ phenotypes_NNS resulting_VBG
        from_IN the_DT combination_NN of_IN the_DT 129_CD and_CC B_NNP 6_CD genomes_NNS may_MD might_MD therefore_RB provide_VB a_DT primed_VBN
        background_NN upon_IN which_WDT the_DT effects_NNS of_IN deficiency_NN in_IN the_DT target_NN gene_NN can_MD be_VB amplified_VBN ._. On_IN the_DT
        other_JJ hand_NN ,_, the_DT autoimmune_JJ phenotype_NN may_MD be_VB overwhelmingly_RB contributed_VBN by_IN the_DT (_( 129_CD ×_NN B_NNP 6_CD )_)
        genomic_JJ combination_NN ,_, with_IN little_JJ if_IN any_DT effect_NN of_IN the_DT deficiency_NN of_IN the_DT KO_NNP gene_NN ._.
        In_IN this_DT issue_NN of_IN 
        PLoS_NNP Biology_NNP ,_, Marina_NNP Botto_NNP and_CC her_PRP$ colleagues_NNS have_VBP tested_VBN this_DT
        hypothesis_NNS by_IN taking_VBG one_CD of_IN their_PRP$ knockout_NN models_NNS for_IN SLE_NNP ,_, the_DT serum_NN amyloid_NN P_NN component_NN
        deficient_NN mouse_NN (_(
        Apcs_NNP
        −_NN /_NN −_NN )_) (_( Bygrave_NNP et_CC al_NN ._. 2004_CD )_) ._. This_DT group_NN has_VBZ published_VBN that_IN 
        Apcs_NNP
        −_NN /_NN −_NN mice_NNS on_IN a_DT (_( 129_CD ×_NN B_NNP 6_CD )_) genetic_JJ background_NN develop_VBP a_DT lupus-like_JJ
        disease_NN ,_, even_RB after_IN repeated_VBN backcrosses_NNS to_TO B_NNP 6_CD (_( Bickerstaff_NNP et_CC al_NN ._. 1999_CD )_) ._. Serum_NNP amyloid_NN P_NN
        component_NN binds_NNS to_TO debris_NN generated_VBN from_IN dying_VBG cells_NNS ._. Efficient_NNP removal_NN of_IN this_DT debris_NN has_VBZ
        been_VBN shown_VBN to_TO be_VB critical_JJ to_TO the_DT prevention_NN of_IN the_DT production_NN of_IN autoantibodies_NNS against_IN
        intracellular_NN material_NN ._. 
        Apcs_NNP was_VBD therefore_RB an_DT interesting_JJ candidate_NN gene_NN to_TO evaluate_VB ._. 
        Apcs_NNP ,_, however_RB ,_, is_VBZ located_VBN in_IN a_DT region_NN near_IN the_DT tip_NN of_IN mouse_NN Chromosome_NNP 1_CD
        that_WDT is_VBZ rich_JJ in_IN SLE_NNP susceptibility_NN loci_NN and_CC in_IN genes_NNS that_WDT have_VBP been_VBN directly_RB associated_VBN
        with_IN SLE_NNP in_IN humans_NNS (_( Wakeland_NNP et_CC al_NN ._. 1999_CD )_) ._. As_IN mentioned_VBN above_IN ,_, the_DT 
        Apcs_NNP
        −_NN /_NN −_NN mouse_NN ,_, although_IN on_IN a_DT mostly_RB B_NNP 6_CD genomic_JJ background_NN ,_, has_VBZ its_PRP$ entire_JJ 
        Apcs_NNP flanking_VBG region_NN replaced_VBN with_IN 129_CD alleles_NNS ._. In_IN a_DT critical_JJ experiment_NN ,_,
        Botto_NNP and_CC colleagues_NNS compared_VBD the_DT autoimmune_JJ phenotypes_NNS of_IN 
        Apcs_NNP
        −_NN /_NN −_NN mice_NNS to_TO congenic_JJ mice_NNS (_( i_NNP ._. e_SYM ._. ,_, genetically_RB identical_JJ ,_, except_IN for_IN the_DT
        gene_NN of_IN interest_NN )_) ,_, carrying_VBG the_DT same_JJ 129_CD region_NN on_IN Chromosome_NNP 1_CD ,_, but_CC expressing_VBG 
        Apcs_NNP ._. Amazingly_NNP ,_, no_DT difference_NN was_VBD found_VBN between_IN the_DT two_CD strains_NNS
        regarding_VBG the_DT production_NN of_IN autoantibodies_NNS ,_, clearly_RB eliminating_VBG 
        Apcs_NNP deficiency_NN as_IN a_DT mechanism_NN for_IN this_DT autoimmune_JJ process_NN ._. 
        Apcs_NNP deficiency_NN was_VBD however_RB associated_VBN with_IN markedly_RB increased_VBN renal_JJ
        damage_NN ,_, suggesting_VBG that_IN this_DT gene_NN may_MD be_VB involved_VBN in_IN preventing_VBG pathological_JJ consequences_NNS
        of_IN autoantibody_NN production_NN ._.
        It_PRP has_VBZ been_VBN reported_VBN anecdotally_RB that_IN the_DT most_RBS common_JJ outcome_NN of_IN a_DT genetic_JJ knockout_NN is_VBZ a_DT
        lupus-like_JJ disease_NN ._. Botto_NNP and_CC her_PRP$ colleagues_NNS may_MD have_VB identified_VBN the_DT reason_NN behind_IN this_DT
        somewhat_RB surprising_JJ observation_NN as_IN a_DT spurious_JJ consequence_NN of_IN the_DT gene-targeting_JJ process_NN ._.
        Gene_NNP targeting_VBG has_VBZ been_VBN an_DT invaluable_JJ tool_NN in_IN understanding_VBG the_DT mechanisms_NNS of_IN immunological_JJ
        diseases_NNS ,_, and_CC has_VBZ still_RB a_DT very_RB important_JJ role_NN to_TO play_VB with_IN increasingly_RB sophisticated_JJ
        techniques_NNS of_IN selective_JJ targeting_VBG ._. The_DT immediate_JJ consequence_NN of_IN this_DT work_NN should_MD be_VB an_DT
        increased_VBN scrutiny_NN for_IN appropriate_JJ controls_NNS ,_, which_WDT may_MD include_VB congenic_JJ mice_NNS carrying_VBG the_DT
        same_JJ 129_CD flanking_VBG region_NN ,_, but_CC expressing_VBG the_DT targeted_VBN gene_NN (_( Figure_NN 2_LS )_) ._.
        The_DT past_JJ few_JJ years_NNS have_VBP shown_VBN that_IN genetic_JJ susceptibility_NN to_TO autoimmune_JJ diseases_NNS
        involves_VBZ a_DT large_JJ number_NN of_IN genes_NNS with_IN small_JJ individual_JJ contributions_NNS ._. In_IN spite_NN of_IN this_DT
        great_JJ complexity_NN ,_, advances_NNS have_VBP been_VBN made_VBN ,_, and_CC a_DT small_JJ but_CC growing_VBG number_NN of_IN susceptibility_NN
        genes_NNS have_VBP been_VBN identified_VBN (_( Morahan_NNP and_CC Morel_NNP 2002_CD )_) ._. A_DT common_JJ trait_NN shared_VBN by_IN successful_JJ
        studies_NNS has_VBZ been_VBN the_DT use_NN of_IN mouse_NN models_NNS ,_, either_CC directly_RB or_CC indirectly_RB ._. As_IN the_DT pace_NN of_IN
        genetic_JJ analysis_NN increases_NNS in_IN autoimmune_JJ diseases_NNS ,_, and_CC powerful_JJ tools_NNS have_VBP been_VBN created_VBN to_TO
        navigate_VB between_IN the_DT mouse_NN and_CC human_JJ genomes_NNS ,_, the_DT use_NN of_IN mouse_NN models_NNS has_VBZ been_VBN reaffirmed_VBD
        at_IN multiple_JJ levels_NNS ._. Mouse_NNP models_NNS are_VBP used_VBN to_TO discover_VB new_JJ susceptibility_NN genes_NNS that_WDT can_MD
        then_RB be_VB assessed_VBN in_IN patient_NN populations_NNS ,_, as_RB well_RB as_IN to_TO validate_NN genes_NNS that_WDT have_VBP been_VBN
        directly_RB identified_VBN in_IN human_JJ genetic_JJ studies_NNS ._. Mouse_NNP models_NNS are_VBP also_RB used_VBN to_TO perform_VB
        detailed_JJ functional_JJ and_CC physiological_JJ analyses_NNS that_WDT cannot_NN be_VB conducted_VBN in_IN humans_NNS ._. Finally_RB ,_,
        mouse_NN models_NNS have_VBP been_VBN invaluable_JJ to_TO screen_VB disease-specific_JJ therapeutic_JJ agents_NNS ._.
        Using_VBG mouse_NN models_NNS has_VBZ its_PRP$ pitfalls_NNS ;_: many_JJ differences_NNS ,_, both_DT obvious_JJ and_CC subtle_JJ ,_, exist_VB
        between_IN mice_NNS and_CC humans_NNS ._. Those_DT differences_NNS are_VBP ,_, however_RB ,_, outweighed_VBN by_IN the_DT power_NN of_IN the_DT
        experimental_JJ system_NN offered_VBN by_IN the_DT mouse_NN ._. What_WP the_DT new_JJ study_NN of_IN Botto_NNP and_CC colleagues_NNS
        reminds_VBZ us_PRP is_VBZ that_IN the_DT appropriate_JJ control_NN is_VBZ still_RB crucial_JJ to_TO meaningful_JJ data_NNS
        interpretation_NN ._. Keeping_VBG that_IN in_IN mind_NN ,_, one_PRP can_MD predict_VB that_IN many_JJ of_IN the_DT keys_NNS to_TO human_JJ
        autoimmune_JJ diseases_NNS are_VBP still_RB in_IN the_DT mouse_NN room_NN ._.
      
    
  
